It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.